This article is more than 5 years old. Information may no longer be current.
Nicox to co-promote latanoprostene bunod with Bausch + Lomb in US
Nicox announced its decision to exercise the option to co-promote latanoprostene bunod with Bausch + Lomb in the US, according to a company press release.
Latanoprostene bunod, a nitric oxide-donating prostaglandin F2-alpha analog, was licensed to Nicox by Bausch + Lomb in 2010. The two companies will begin negotiations of a co-promotion agreement to be signed at a later time, according to the release.
The drug is currently being tested in two pivotal phase 3 clinical trials, APOLLO and LUNAR, for the potential treatment of glaucoma and ocular hypertension.
Top-line efficacy results from the APOLLO study are expected in the third quarter of 2014, and results from the LUNAR study are expected in the fourth quarter of 2014, according to the release.
Latanoprostene bunod is pending U.S. Food and Drug Administration approval and could be launched in 2016, according to the release